In xenografts derived from the breast cancer cell line MCF7 and the pancreatic carcinoid cell line BON, both harboring an activating PIK3CA mutation, treatment with the allosteric mTOR inhibitor Rapamycin (Sirolimus) was associated with a significant decrease in tumor volume (Meric-Bernstam et al., 2012). Here, MTOR is linked to breast carcinoma.